{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:27:45Z","timestamp":1786717665807,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Thorac Med"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/1817-1737.185762","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T06:01:59Z","timestamp":1467871319000},"page":"224","source":"Crossref","is-referenced-by-count":13,"title":["Pulmonary eosinophilia associated to treatment with natalizumab"],"prefix":"10.4103","volume":"11","author":[{"given":"MMarisol","family":"Dominguez-Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Curto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Munteis-Olivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Balcells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1817-1737.185762-1","first-page":"557","volume-title":"Eosinophilic lung diseases","author":"Cottin","year":"2012","journal-title":"Immunol Allergy Clin North Am"},{"key":"key-10.4103\/1817-1737.185762-2","first-page":"649","volume-title":"Eosinophilic pneumonias","author":"Akuthota","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"key-10.4103\/1817-1737.185762-3","first-page":"192","volume-title":"Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia","author":"Solomon","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"key-10.4103\/1817-1737.185762-4","first-page":"899","volume-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1817-1737.185762-5","first-page":"375","volume-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1817-1737.185762-6","first-page":"1561","volume-title":"Hypereosinophilia in patients with multiple sclerosis treated with natalizumab","author":"Abbas","year":"2011","journal-title":"Neurology"},{"key":"key-10.4103\/1817-1737.185762-7","first-page":"639","volume-title":"Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis","author":"Hradilek","year":"2014","journal-title":"Mult Scler"},{"key":"key-10.4103\/1817-1737.185762-8","first-page":"1009","volume-title":"Cavitary pulmonary disease in a patient treated with natalizumab","author":"de","year":"2014","journal-title":"Presse Med"},{"key":"key-10.4103\/1817-1737.185762-9","first-page":"239","volume-title":"A method for estimating the probability of adverse drug reactions","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Annals of Thoracic Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:27:10Z","timestamp":1786714030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1817-1737.185762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"alternative-id":["185762"],"URL":"https:\/\/doi.org\/10.4103\/1817-1737.185762","relation":{},"ISSN":["1817-1737"],"issn-type":[{"value":"1817-1737","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}